NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer previously treated with crizotinib because no evidence submission was received from Roche. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance

  • National Institute for Health and Care Excellence (NICE)